Rolf M Vornhagen

Title: Rolf M Vornhagen: Innovator in Monoclonal Antibody Development

Introduction

Rolf M Vornhagen is a notable inventor based in Langen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for medical research and therapeutic applications.

Latest Patents

Rolf M Vornhagen holds a patent for a monoclonal antibody that recognizes a structure common to human interleukin-2 and the light lambda chain of human immunoglobulin. This innovative approach involves immunizing animals, especially mice, with human interleukin-2 (TCGF) and fusing the splenocytes obtained from these animals with mouse myeloma cells to create hybridomas. The hybridomas are then raised as clones, and the antibodies produced are tested for their specificity to human interleukin-2 (TCGF). Clones that produce the desired antibodies are selected for further cultivation, leading to the preparation of the antibody, which is harvested from the culture medium or ascitic fluids of the animal.

Career Highlights

Rolf M Vornhagen is associated with Biotest-Serum-Institut GmbH, where he has contributed to advancements in immunology and biotechnology. His work has been instrumental in the development of therapeutic antibodies that can be used in various medical applications.

Collaborations

Rolf has collaborated with notable colleagues such as Hans H Sonneborn and Udo Schwulera. Their combined expertise has furthered research in the field of monoclonal antibodies and their applications.

Conclusion

Rolf M Vornhagen's contributions to the field of monoclonal antibodies exemplify the importance of innovation in biotechnology. His work continues to influence medical research and therapeutic development.